Introduction {#s1}
============

The production of extended-spectrum β-lactamases (ESBLs) is the most common mechanism of resistance to third-generation cephalosporins in *Enterobacteriaceae* bacteria, especially *Escherichia coli* and *Klebsiella pneumoniae*. Carbapenems are the drugs of last resort to treat severe infections caused by pathogens that produce ESBLs [@pone.0026356-Anderson1]--[@pone.0026356-Lee1]. Although the rates of resistance to carbapenems are low, they have been increasing [@pone.0026356-Landman1]. During the past decade the spread of antibiotic resistance in *Enterobacteriaceae* isolates, especially the increase in *K. pneumoniae* carbapenemase (KPC)-producing isolates, has become a major concern worldwide [@pone.0026356-Elizabeth1]. Infections due to KPC-producing isolates have become an important challenge in healthcare settings [@pone.0026356-James1]. The rapid emergence of carbapenem-resistant *Enterobacteriaceae* isolates in our hospital was revealed by bacterial surveillance data. The rate of resistance to imipenem in *K. pneumoniae* rose from 1.3% in 2006 to 11.1% in 2009, whereas the rate in *E. coli* rose from 0.3% 2006 to 1.0% in 2009 (data not shown).

The production of carbapenemases, especially KPC-type carbapenemases, is the most common mechanism for carbapenem resistance in *Enterobacteriaceae* isolates [@pone.0026356-Lledo1]--[@pone.0026356-MunozPrice1]. However, the detection of carbapenemases can be difficult because, for some carbapenemase-producing *Enterobacteriaceae*, the minimum inhibitory concentration (MIC) of carbapenem is high but still within the susceptible range as defined by the Clinical and Laboratory Standards Institute (CLSI) criteria [@pone.0026356-Elizabeth1], [@pone.0026356-Pasteran1]--[@pone.0026356-Clinical1]. In 2009, the CLSI recommended the modified Hodge test (MHT) to screen for the production of carbapenemase in *Enterobacteriaceae* isolates with elevated MICs for carbapenems or reduced inhibition zones as measured by disc diffusion. The criteria were a diameter for the inhibition zones for meropenem and ertapenem of 19--21 mm and 16--21 mm, respectively, and MIC values of 2 µg/mL and 2--4 µg/mL, respectively (carbapenem breakpoints have been changed in M100-S20-U and M100-S21. According the new criteria, the initial screen test and the confirmatory test by MHT are no longer necessary for routine patient testing). Although the sensitivity and specificity of the MHT have been shown to exceed 90%, several studies have reported false positive or false negative results when this method was used to screen for carbapenemase in *Enterobacteriaceae* isolates [@pone.0026356-Pasteran1], [@pone.0026356-Cecilia1]. In this study, we investigated the rate of false positives obtained when the MHT was used to test ESBL-producing and carbapenemase-nagetive *E. coli* and *K. pneumoniae* clinical isolates that did not conform to the CLSI criteria for carbapenemase screening.

Materials and Methods {#s2}
=====================

Bacterial strains {#s2a}
-----------------

Three hundred and one non-duplicate clinical isolates were analysed. The isolates included 153 *E. coli* isolates and 148 *K. pneumoniae* isolates and had been collected from January to December 2008 in Huashan Hospital, Fudan University, Shanghai, China. All the isolates produced ESBLs, as confirmed by the CLSI phenotypic confirmatory test initially, but were susceptible to carbapenems (zones of inhibition of ≥19 mm in diameter for ertapenem and ≥16 mm for meropenem, respectively) (9). As control, 18 carbapenem-resistant, KPC-2 type carbapenemase-producing *K. pneumoniae* clinical isolates were used in this study (11).

Antimicrobial susceptibility testing and the MHT {#s2b}
------------------------------------------------

Antimicrobial susceptibility testing was performed using agar dilution methods recommended by the CLSI (9). Minimal inhibitory concentrations (MICs) of cefazolin, cefoxitin, cefotaxime, ceftriaxone, aztreonam, ceftazidime, cefepime, ertapenem, imipenem, meropenem, and piperacillin/tazobactam were determined in accordance with the CLSI criteria (9). The MHT was carried out on all isolates to detect carbapenemase using ertapenem and meropenem as described by the CLSI (9). A well characterized strain of *C. freundii* that produced IMP-9-type metallo-β-lactamase (MBL) and *E. coli* strain ATCC 25922 were used as positive and negative controls, respectively.

Carbapenem inactivation assay {#s2c}
-----------------------------

In order to determine whether resistance to imipenem and meropenem was likely caused by production of carbapenemase, a disk diffusion bioassay was performed on Mueller-Hinton agar with imipenem, meropenem and ertapenem disks as described by Yigit et al [@pone.0026356-Yigit1].

Genotypic detection of β-Lactamase {#s2d}
----------------------------------

The β-lactamase genes *TEM*, *SHV*, *PER*, *SFO*, *VEB*, *CTX-M* and *GES*, and carbapenemases including *KPC*, *VIM*, *IPM*, *SPM*, *SME*, *GIM*, *NMC*, *IMI*, *IND* and *OXA*, were investigated in all of clinical strains using previously described primers [@pone.0026356-Patrick1]--[@pone.0026356-Woodford1]. Conserved primers, forward primer KPC-F (5′-AGGACTTTGGCGGCTCCAT-3′) and reverse primer KPC-R (5′-TCCCTCGAGCGCGAGTCTA-3′), were designed against the *KPC* gene to detect the *KPC*-1 to *KPC*-11 sequences according to the published nucleotide sequences in Genbank, which encode different KPC-type carbapenemases and produced a 748-bp PCR product. PCR amplicons were sequenced, and the DNA sequences obtained were compared to the available sequences via National Center for Biotechnology Information BLAST search.

Analysis of outer membrane proteins {#s2e}
-----------------------------------

The outer membrane proteins of all isolates with false-positive result on MHT were examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis, as described previously [@pone.0026356-Hosaka1].

Ethics Statement {#s2f}
----------------

As this study was focused on bacterial isolates collected from routine samples, approval from ethics committee at Fudan University was not necessary. Neither was there any need for informed consent procedures as no extra sampling was performed and no personal data was stored in relation to the isolates.

Results {#s3}
=======

Antimicrobial susceptibility testing {#s3a}
------------------------------------

The results of the antimicrobial susceptibility testing indicated that, for the 301 isolates tested, the inhibition zones for meropenem and ertapenem all had a diameter greater than 22 mm, and the MIC values were all below 1 µg/mL. Therefore, none of the isolates conformed to the CLSI criteria for carbapenemase screening (namely, diameters for meropenem and ertapenem of 19--21 mm and 16--21 mm, respectively, and MIC values of 2 µg/mL and 2--4 µg/mL, respectively.). None of the isolates was found to be susceptible to cefazolin and 99.7%, 62.1%, 48.2%, and 19.9% were resistant to cefotaxime, ceftazidime, cefepime, and cefoxitin, respectively. The susceptibility rates for imipenem, meropenem, and ertapenem were 100.0%, 100.0%, and 100.0%, respectively ([Table 1](#pone-0026356-t001){ref-type="table"}).

10.1371/journal.pone.0026356.t001

###### Antimicrobial activities of various antimicrobial agents against 301 *E. coli* and *K. pneumoniae* isolates.

![](pone.0026356.t001){#pone-0026356-t001-1}

  Drug                       MIC (µg/ml)    S (%)   R (%)          
  ------------------------- -------------- ------- ------- ------- -------
  Imipenem                   ≤0.06--0.25    ≤0.06   ≤0.06   100.0    0.0
  Meropenem                  ≤0.06--0.25    ≤0.06   ≤0.06   100.0    0.0
  Ertapenem                  ≤0.06--0.25    ≤0.06   0.125   100.0    0.0
  Cefepime                   0.125--\>128    16      64     30.9    48.2
  Ceftazidime                0.25--\>128     32     \>128   27.9    62.1
  Cefotaxime                 0.125--\>128    128    \>128    0.3    99.7
  Ceftriaxone                0.125--\>128   \>128   \>128    0.3    99.7
  Cefoxitin                    1--\>128       8      128    62.8    19.9
  Cefazolin                   128--\>128    \>128   \>128    0.0    100.0
  Piperacillin-tazobactam     0.5--\>128      8     \>128   65.8    23.9
  Aztreonam                  0.25--\>128     64     \>128    8.6    83.1

PCR amplification of β-lactamase genes and the MHT {#s3b}
--------------------------------------------------

Of the 301 *E. coli* and *K. pneumoniae* isolates, none produced carbapenemase. Genes that encoded the CTX-M-type ESBLs were detected in 280 (93.0%) of the isolates, among which CTX-M-14, CTX-M-15, CTX-M-25, CTX-M-14 coupled with CTX-M-15, and CTX-M-14 coupled with CTX-M-25 type ESBL were found in 135 (48.2%), 112 (40.0%), 2 (0.7%), 28 (10.0%), and 3 (1.1%) of the isolates, respectively. Among 301 isolates, 18.3% were producing more than two types of ESBLs, such as TEM-type and CTX-M-type ESBLs, SHV-type and CTX-M-type ESBLs ([Table 2](#pone-0026356-t002){ref-type="table"}). Although all the isolates were sensitive to carbapenems and carbapenemase-negative, the MHT yielded a positive result ([Figure 1](#pone-0026356-g001){ref-type="fig"}) for 3.3% (10/301) of the isolates and all the MHT-positive isolates (except one isolate was SHV-12 type ESBL producer) were CTX-M type ESBL producing ([Table 3](#pone-0026356-t003){ref-type="table"}). Among 18 carbapenem-resistant *K. pneumoniae* clinical isolates, all were produced KPC-2 type carbapenemase and all were producing a positive result of MHT.

![False-positive result on MHT.\
A, K2821 *K. pneumoniae* (KPC-2 carbapenemase producer). B, 08-438 *E.coli*. C, 08-97 *K. pneumoniae*. D, *E. coli* ATCC 25922.](pone.0026356.g001){#pone-0026356-g001}

10.1371/journal.pone.0026356.t002

###### Distribution of ESBL genes among the 301 *E. coli* and *K. pneumoniae* isolates.

![](pone.0026356.t002){#pone-0026356-t002-2}

  ESBL genes                                                              Genotype                                            Number                   \%
  --------------------------------------------- ------------------------------------------------------------- -------------------------------------- -------
  SVH-type ESBLs                                                SHV-2, SHV-12, SHV-28, SHV-31                                   8                      2.7
  CTX-M-type ESBLs                                              CTX-M-14, CTX-M-15, CTX-M-25                   243[\*](#nt101){ref-type="table-fn"}   80.7
  TEM + CTX-type ESBLs                                       TEM-40, TEM-135, CTX-M-14, CTX-M-15                                3                      1.0
  SHV + CTX-M-type ESBLs                         SHV-2, SHV-12, SHV-28, SHV-31, CTX-M-14, CTX-M-15, CTX-M-25                    34                    11.3
  Negative[\*\*](#nt102){ref-type="table-fn"}                                                                                   13                     4.3
  Total                                                                                                                        301                    100.0

\*: 9.0% (22/243) isolates were producing both CTX-M-14 and CTX-M-15 type ESBL, and 1.2% (3/243) isolates were producing both CTX-M-14 and CTX-M-25 type ESBL.

\*\*: We did not detected the TEM, SHV or CTX-M type ESBLs among these isolates.

10.1371/journal.pone.0026356.t003

###### The characteristics of the 10 false-positive isolates by MHT.

![](pone.0026356.t003){#pone-0026356-t003-3}

  Number        Organism       MIC (mg/L)   ESBLs genes                  
  --------- ----------------- ------------ ------------- ------- ------- ------------------
  08-309        *E. coli*         128            2          4     ≤0.06       CTX-M-14
  08-318        *E. coli*        \>128          128         8     ≤0.06       CTX-M-15
  08-438        *E. coli*         128           32        \>128   ≤0.06       CTX-M-15
  08-547        *E. coli*          64            4         16     ≤0.06       CTX-M-14
  08-1002       *E. coli*         128           16          8     ≤0.06       CTX-M-15
  08-1039       *E. coli*         128            2          4     ≤0.06       CTX-M-14
  08-97      *K. pneumoniae*     \>128         \>128        4     ≤0.06   CTX-M-15, SHV-28
  08-1105    *K. pneumoniae*     \>128          128         4     ≤0.06       CTX-M-15
  08-466     *K. pneumoniae*       64          \>128       128    0.125        SHV-12
  08-893     *K. pneumoniae*     \>128          128         4     ≤0.06   CTX-M-15, SHV-61

Carbapenem inactivation assay {#s3c}
-----------------------------

A carbapenem inactivation assay performed on all 301 carbapenems-susceptible isolates indicated that alterations in shape of the zones of inhibition around the test organism were not observed, suggesting no carbapenemase was involved in hydrolysis of carbapenems in these isolates. However The assay of all 18 KPC-2 type carbapenemase-producing *K. pneumoniae* isolates were positive.

Analysis of outer membrane proteins {#s3d}
-----------------------------------

Analysis of the outer membrane porin proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis showed that all 10 isolates (except 08-438 *E.coli*) exhibited loss of one of porin protein compared with the sensitive strains ([Figure 2](#pone-0026356-g002){ref-type="fig"} and [Figure 3](#pone-0026356-g003){ref-type="fig"}). This suggests that the outer membrane porin proteins might play an important role in resulting to the false-positive result.

![1. *E.coli* ATCC 25922, 2. 08-309 *E.coli*, 3. 08-318 *E.coli*, 4. 08-438 *E.coli*, 5. *E.coli* ATCC 25922, 6. 08-547 *E.coli*, 7. 08-1002 *E.coli*, 8. 08-1039 *E.coli*, M. Marker.](pone.0026356.g002){#pone-0026356-g002}

![1. K1933 *K. Pneumoniae* (Sensitive to cefazolin, no ESBL and carbapenemase producer), 2. 08-97 *K. Pneumoniae*, 3. 08-1105 *K. Pneumoniae*, 4. 08-466 *K. Pneumoniae*, 5. 08-893 *K. Pneumoniae*, M. Marker.](pone.0026356.g003){#pone-0026356-g003}

Discussion {#s4}
==========

Given the increasing prevalence of carbapenemase-producing *Enterobacteriaceae* isolates worldwide [@pone.0026356-Elizabeth1], simple and accurate tests are needed to detect isolates that produce carbapenemase. For this purpose, the CLSI have recommended the MHT for the detection of carbapenemase in *Enterobacteriaceae* isolates. Although the MHT is a simple method for detecting carbapenemase-positive isolates, false positive results are obtained occasionally [@pone.0026356-Pasteran1], [@pone.0026356-Cecilia1]. In June 2010, CLSI changed the carbapenem breakpoints and reviewed the recommendation on carbapenemase detection by MHT among *Enterobacteriacea* (M100-S20-U) and informed that MHT would not be recommended, except for epidemiological or infection control purposes.. In this study, we used carbapenem-susceptible *E. coli* and *K. pneumoniae* isolates that did not conform to the CLSI criteria for screening for the presence of carbapenemase. False positive results for the MHT were obtained among 3.3% of the isolates. We presume that the false positive results are probably due to low-level hydrolysis of ertapenem by ESBLs, particularly those of the CTX-M type, because we found that 97.3% of the isolates in our study produced CTX-M-type ESBLs [@pone.0026356-Cecilia1], [@pone.0026356-Girlich1].

Although the false positive results were observed in our study, MHT is not recommended (and never was) to detect carbapenemase among isolates that yielded negative-result on screening test. Whether for epidemiological or infection control purposes, adequate detection of the production of carbapenemase in *Enterobacteriaceae* isolates is crucial for infection control measures and the appropriate choice of antimicrobial therapy [@pone.0026356-Pasteran1]. To improve the detection of carbapenemase-producing *Enterobacteriaceae* in clinical microbiology laboratories, several phenotypic tests to detect KPCs have been developed [@pone.0026356-Tsakris1]--[@pone.0026356-Tsakris3]. In addition to the MHT, a second phenotypic method has been shown to be promising for the identification of KPCs. This method utilizes boronic acid and 3-aminophenyl boronic acid-based compounds, and has proved to be highly sensitive and specific for the detection of KPCs.

In summary, as reported, CTX-M-type ESBLs might be hydrolysing the ertapenem used in the assay [@pone.0026356-Girlich1]. Clinical laboratories must be aware that false positive results may occur, especially in geographical areas where the incidence of isolates that produce CTX-M-type ESBLs is relatively high, such as the Asia-Pacific region [@pone.0026356-Bell1]. Hence, further work is necessary to determine the frequency of false positive results when the MHT is used to detect carbapenemase production in *Enterobacteriaceae* isolates and more accurate methods should be developed for use in clinical microbiology laboratories.
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